Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Construction In Progress: ¥0.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
68 GF Score
Price ¥7.52
GF Value ¥5.35
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Construction In Progress?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co SHSE:688505 +1.08% 68 Construction In Progress is ¥0.6 Mil as of Jun. 2026. GuruFocus rates SHSE:688505 with a GF Score™ of 68/100 and a GF Value™ of ¥5.35 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's quarterly construction in progress declined from Jun. 2025 (¥10.5 Mil) to Dec. 2025 (¥0.6 Mil) and declined from Dec. 2025 (¥0.6 Mil) to Jun. 2026 (¥0.6 Mil).

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annual construction in progress declined from Dec. 2023 (¥274.9 Mil) to Dec. 2024 (¥13.1 Mil) and declined from Dec. 2024 (¥13.1 Mil) to Dec. 2025 (¥0.6 Mil).

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Construction In Progress Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.54 180.00 274.86 13.07 0.64

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun16 Dec16 Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.20 13.07 10.51 0.64 0.59
SHSE:688505
68GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥0.6 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a Construction In Progress of ¥0.6 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Construction In Progress too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Construction In Progress is ¥0.6 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Construction In Progress compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Construction In Progress of ¥0.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Construction In Progress is ¥0.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.35, compared to a current price of ¥7.52 — trading 40.6% above its estimated fair value. The current Construction In Progress is ¥0.6 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current Construction In Progress is ¥0.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥7.52 is trading 40.6% above its estimated GF Value™ of ¥5.35. GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:688505:

  • Construction In Progress: ¥0.6 Mil
  • GF Value™: ¥5.35 vs. price of ¥7.52 (40.6% above fair value)
  • GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
68GF Score

Get the complete analysis for SHSE:688505

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.52
Price
¥5.35
GF Value